Esperion Therapeutics | ESPR - تكلفة المبيعات





تكلفة المبيعات تغيير تاريخ
AbbVie USD 4.55B 757M 2025-12
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
Amarin USD 26.05M 1.41M 2025-12
Amgen USD 1.79B 128M 2025-12
Biogen USD 810.1M 205.1M 2025-09
BioMarin Pharmaceutical USD 161.56M 16.62M 2025-12
Cipla INR 29.1B 1.16B 2025-12
CSL USD 3.87B 2.08B 2025-12
Cytokinetics USD 99.23M 13.32M 2025-09
Daiichi Sankyo JPY 118.28B 37.7B 2025-12
Eli Lilly USD 3.37B 363.7M 2025-12
Esperion Therapeutics USD 27.85M 13.43M 2025-12
Geron USD 1.31M 263K 2025-12
Grifols EUR 1.51B 184.45M 2025-12
Halozyme Therapeutics USD 102.15M 29.14M 2025-12
Heron Therapeutics USD 11.12M 795K 2025-12
Ionis Pharmaceuticals USD 8M 5.66M 2025-12
Merck USD 3.32B 531M 2025-12
Minerva Neurosciences 386K 31K 2024-06
Moderna USD 452M 245M 2025-12
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Pfizer USD 6.29B 2.12B 2025-12
PTC Therapeutics USD 16.3M 7.02M 2025-12
Puma Biotechnology USD 29.1M 18.44M 2024-09
Regeneron Pharmaceuticals USD 584.6M 63M 2025-12
Sanofi EUR 4.29B 421M 2025-12
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
United Therapeutics USD 474.7M 373.8M 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12